However, the differences in phenotypes between sputum eosinophils in the examined groups might indicate the future direction of personalized therapy in COPD and asthma, e.g., with CCR3 monoclonal antibody. This evidence concerns the gene CCR3 and chronic obstructive pulmonary disease.